

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3052823/publications.pdf>

Version: 2024-02-01

111  
papers

10,297  
citations

76326

40  
h-index

33894

99  
g-index

123  
all docs

123  
docs citations

123  
times ranked

14396  
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. <i>European Heart Journal</i> , 2022, 43, 1715-1727.	2.2	40
2	Impacto de la función renal en el valor pronóstico del metabolismo mineral en pacientes con cardiopatía isquémica crónica. <i>Clínica E Investigación En Arteriosclerosis</i> , 2022, 34, 1-9.	0.8	1
3	Impact of renal function on the prognostic value of mineral metabolism in patients with chronic ischaemic heart disease patients with chronic ischaemic heart disease. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2022, , .	0.2	0
4	Paced P-wave duration as a significant predictor for atrial high-rate episodes in patients with cardiac implantable electronic devices. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2022, 45, 832-838.	1.2	2
5	NT-proBNP Levels Influence the Prognostic Value of Mineral Metabolism Biomarkers in Coronary Artery Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 4153.	2.4	1
6	PCSK9 and HS-CRP Predict Progression of Aortic Stenosis in Patients with Stable Coronary Artery Disease. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 238-245.	2.4	6
7	Prognostic value of initial QRS analysis in anterior STEMI: Correlation with left ventricular systolic dysfunction, serum biomarkers, and cardiac outcomes. <i>Annals of Noninvasive Electrocardiology</i> , 2021, 26, e12791.	1.1	5
8	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021, 44, 1219-1227.	8.6	19
9	MCP-1 Predicts Recurrent Cardiovascular Events in Patients with Persistent Inflammation. <i>Journal of Clinical Medicine</i> , 2021, 10, 1137.	2.4	14
10	Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy. <i>ESC Heart Failure</i> , 2021, 8, 2856-2865.	3.1	22
11	Parathormone levels add prognostic ability to N-terminal pro-brain natriuretic peptide in stable coronary patients. <i>ESC Heart Failure</i> , 2021, 8, 2713-2722.	3.1	10
12	Anti-Inflammatory Drugs in Patients with Ischemic Heart Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2835.	2.4	5
13	N-Terminal Pro-Brain Natriuretic Peptide Plasma Levels Are Associated with Intermediate-Term Follow-Up Cancer in Coronary Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 4042.	2.4	2
14	Statin use is associated with reduced mortality after respiratory viral infection. <i>ERJ Open Research</i> , 2021, 7, 00365-2020.	2.6	4
15	Beta-blocker therapy in elderly patients with renal dysfunction and heart failure. <i>Journal of Geriatric Cardiology</i> , 2021, 18, 20-29.	0.2	0
16	Comparison of Outcomes of Catheter Ablation in Asymptomatic Versus Symptomatic Preexcitation to Guidelines and Beyond. <i>American Journal of Cardiology</i> , 2021, 161, 51-55.	1.6	0
17	Detecting Atrial Fibrillation in Patients With an Embolic Stroke of Undetermined Source (from the Tj ETQq1 1 0.784314 rgBT /Overlook	1.6	15
18	Monocyte Chemoattractant Protein-1 Is an Independent Predictor of Coronary Artery Ectasia in Patients with Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 3037.	2.4	7

#	ARTICLE	IF	CITATIONS
19	Anticuerpos monoclonales inhibidores de la proproteÃ­na convertasa subtilisina/kexina tipo 9: nuevas evidencias. Revista Espanola De Cardiologia Suplementos, 2020, 20, 15-20.	0.2	1
20	Cardiovascular Damage in COVID-19: Therapeutic Approaches Targeting the Renin-Angiotensin-Aldosterone System. International Journal of Molecular Sciences, 2020, 21, 6471.	4.1	21
21	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. European Heart Journal, 2020, 41, 4114-4123.	2.2	35
22	An accessory chord in a wrong place. European Heart Journal - Case Reports, 2020, 4, 1-2.	0.6	0
23	Galectin-3 is Associated with Cardiovascular Events in Post-Acute Coronary Syndrome Patients with Type-2 Diabetes. Journal of Clinical Medicine, 2020, 9, 1105.	2.4	15
24	Takotsubo syndrome after mitral valve surgery: a case report. European Heart Journal - Case Reports, 2020, 4, 1-5.	0.6	5
25	Advanced interatrial block: An electrocardiographic marker for stroke recurrence. Journal of Electrocardiology, 2019, 57, 1-5.	0.9	13
26	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology, 2019, 7, 618-628.	11.4	207
27	Blockade of Renin-Angiotensin-Aldosterone System in Elderly Patients with Heart Failure and Chronic Kidney Disease: Results of a Single-Center, Observational Cohort Study. Drugs and Aging, 2019, 36, 1123-1131.	2.7	8
28	Bicuspid aortic valve behaviour in elite athletes. European Heart Journal Cardiovascular Imaging, 2019, 20, 772-780.	1.2	30
29	Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Cardiovascular Research, 2019, 115, 10-19.	3.8	72
30	The other side of anticoagulant therapy. REC: CardioClinics, 2019, 54, 208-210.	0.1	1
31	Cardiac Arrest With ST-Segment Elevation in V1 and V2. Circulation, 2018, 137, 1742-1744.	1.6	4
32	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal, 2018, 39, 763-816.	2.2	2,305
33	Editor's Choice 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Journal of Vascular and Endovascular Surgery, 2018, 55, 305-368.	1.5	734
34	Response by Arroyo Rivera et al to Letters Regarding Article, "Cardiac Arrest With ST-Segment Elevation in V1 and V2: Differential Diagnosis". Circulation, 2018, 138, 2073-2074.	1.6	0
35	Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. European Journal of Preventive Cardiology, 2018, 25, 948-955.	1.8	46
36	Future directions for therapeutic strategies in post-ischaemic vascularization: a position paper from European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology. Cardiovascular Research, 2018, 114, 1411-1421.	3.8	19

#	ARTICLE	IF	CITATIONS
37	Development and validation of a new questionnaire measuring treatment satisfaction in patients with non-valvular atrial fibrillation: SAFUCA <sup>®</sup> . <i>Quality of Life Research</i> , 2017, 26, 767-778.	3.1	5
38	Microvesicles in vascular homeostasis and diseases. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1296-1316.	3.4	193
39	Use of Proton-Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease. <i>PLoS ONE</i> , 2017, 12, e0169826.	2.5	21
40	Comparison of 3 Predictive Clinical Risk Scores in 603 Patients with Stable Coronary Artery Disease. <i>Texas Heart Institute Journal</i> , 2017, 44, 239-244.	0.3	2
41	Reference Values of Aortic Root in Male and Female White Elite Athletes According to Sport. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	2.6	70
42	Design and rationale of a multicentre, randomised, double-blind, placebo-controlled clinical trial to evaluate the effect of vitamin D on ventricular remodelling in patients with anterior myocardial infarction: the VITamin D in Acute Myocardial Infarction (VITDAMI) trial. <i>BMJ Open</i> , 2016, 6, e011287.	1.9	7
43	Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 685-693.	4.0	29
44	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016, 37, 2999-3058.	2.2	2,393
45	Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential. <i>Expert Review of Proteomics</i> , 2016, 13, 857-871.	3.0	11
46	Parathormone levels are independently associated with the presence of left ventricular hypertrophy in patients with coronary artery disease. <i>Journal of Nutrition, Health and Aging</i> , 2016, 20, 659-664.	3.3	11
47	Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate. <i>Journal of Bone and Mineral Metabolism</i> , 2016, 34, 587-598.	2.7	13
48	Plasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease. <i>PLoS ONE</i> , 2016, 11, e0152816.	2.5	12
49	The Prognostic Value of High-Sensitive Troponin I in Stable Coronary Artery Disease Depends on Age and Other Clinical Variables. <i>Cardiology</i> , 2015, 132, 1-8.	1.4	15
50	Novel methodologies for biomarker discovery in atherosclerosis. <i>European Heart Journal</i> , 2015, 36, 2635-2642.	2.2	174
51	Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors. <i>Journal of Cardiology</i> , 2015, 66, 22-27.	1.9	15
52	Targeting metabolic disturbance in the diabetic heart. <i>Cardiovascular Diabetology</i> , 2015, 14, 17.	6.8	44
53	N-Terminal Pro-Brain Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in Patients with Coronary Artery Disease. <i>PLoS ONE</i> , 2015, 10, e0126741.	2.5	15
54	Patient-Prosthesis Mismatch in Patients Undergoing Bioprosthetic Aortic Valve Implantation Increases Risk of Reoperation for Structural Valve Deterioration. <i>Journal of Cardiac Surgery</i> , 2014, 29, 439-444.	0.7	17

#	ARTICLE	IF	CITATIONS
55	Networks for improving care in patients with acute coronary syndrome: A framework. <i>Acute Cardiac Care</i> , 2014, 16, 41-48.	0.2	2
56	Usefulness of a Combination of Monocyte Chemoattractant Protein-1, Galectin-3, and N-Terminal Probrain Natriuretic Peptide to Predict Cardiovascular Events in Patients With Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2014, 113, 434-440.	1.6	66
57	DiagnÃ³stico de amiloidosis cardiaca por lesiones cutÃ¡neas. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 666.	1.2	3
58	Coexistence of Low Vitamin D and High Fibroblast Growth Factor-23 Plasma Levels Predicts an Adverse Outcome in Patients with Coronary Artery Disease. <i>PLoS ONE</i> , 2014, 9, e95402.	2.5	44
59	Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. <i>Cardiovascular Diabetology</i> , 2013, 12, 172.	6.8	59
60	Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms. <i>PLoS ONE</i> , 2013, 8, e78330.	2.5	76
61	Statin Use in Aortic Aneurismal Disease to Prevent Progression and Cardiovascular Events: Review of Experimental and Clinical Data. <i>Current Vascular Pharmacology</i> , 2013, 11, 299-304.	1.7	10
62	Vitamin D receptor activation and cardiovascular disease. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, iv17-iv21.	0.7	54
63	Patients with neovascular age-related macular degeneration in Spain display a high cardiovascular risk. <i>European Journal of Ophthalmology</i> , 2012, 22, 404-411.	1.3	15
64	Phosphate: a stealthier killer than previously thought?. <i>Cardiovascular Pathology</i> , 2012, 21, 372-381.	1.6	60
65	Study of the capillary electrophoresis profile of intact Î±-1-acid glycoprotein isoforms as a biomarker of atherothrombosis. <i>Analyst</i> , The, 2011, 136, 816-822.	3.5	32
66	Metabolites Secreted by Human Atherothrombotic Aneurysms Revealed through a Metabolomic Approach. <i>Journal of Proteome Research</i> , 2011, 10, 1374-1382.	3.7	31
67	ProteÃ³mica cardiovascular: una nueva tecnologÃ­a para resolver viejos problemas. <i>ClÃ­nica E InvestigaciÃ³n En Arteriosclerosis</i> , 2011, 23, 183-185.	0.8	0
68	Targeted and non-targeted metabolic time trajectory in plasma of patients after acute coronary syndrome. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 56, 343-351.	2.8	24
69	Proteomic and Metabolomic Profiles in Atherothrombotic Vascular Disease. <i>Current Atherosclerosis Reports</i> , 2010, 12, 202-208.	4.8	26
70	Proteomic Strategies in the Search of New Biomarkers in Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2009-2016.	2.8	41
71	Leukotriene B4 enhances the activity of nuclear factor-Î² pathway through BLT1 and BLT2 receptors in atherosclerosis. <i>Cardiovascular Research</i> , 2009, 81, 216-225.	3.8	114
72	The Proteomic Approach in the Development of Prognostic Biomarkers in Atherothrombosis. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2009, 4, 25-30.	1.5	5

#	ARTICLE	IF	CITATIONS
73	Plasma fingerprinting with GC-MS in acute coronary syndrome. <i>Analytical and Bioanalytical Chemistry</i> , 2009, 394, 1517-1524.	3.7	88
74	Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome. <i>Proteomics</i> , 2009, 9, 1982-1993.	2.2	23
75	Cardiovascular Risk and Antiangiogenic Therapy for Age-related Macular Degeneration. <i>Survey of Ophthalmology</i> , 2009, 54, 339-348.	4.0	47
76	Improving Metabolite Knowledge in Stable Atherosclerosis Patients by Association and Correlation of GC-MS and <sup>1</sup> H NMR Fingerprints. <i>Journal of Proteome Research</i> , 2009, 8, 5580-5589.	3.7	70
77	Biomarkers in Cardiovascular Medicine. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2009, 62, 677-688.	0.6	28
78	Biomarcadores en la medicina cardiovascular. <i>Revista Espanola De Cardiologia</i> , 2009, 62, 677-688.	1.2	47
79	Respuesta. <i>Revista Espanola De Cardiologia</i> , 2009, 62, 1342-1343.	1.2	0
80	Proteomics in atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2008, 10, 209-215.	4.8	12
81	Effect of Intensive Atorvastatin Therapy on Prostaglandin E2 Levels and Metalloproteinase-9 Activity in the Plasma of Patients With Non-ST-Elevation Acute Coronary Syndromeâ€”Conflicts of interest: Drs. Egido and TuÃ±Ã³n have participated on advisory boards and have been invited speakers for Pfizer. <i>American Journal of Cardiology</i> , 2008, 102, 12-18.	1.6	42
82	Soluble Fas ligand plasma levels are associated with forearm reactive hyperemia in subjects with coronary artery disease. <i>Atherosclerosis</i> , 2008, 201, 407-412.	0.8	20
83	Circulating Human Monocytes in the Acute Coronary Syndrome Express a Characteristic Proteomic Profile. <i>Journal of Proteome Research</i> , 2007, 6, 876-886.	3.7	52
84	Mechanisms of action of statins in stroke. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 273-278.	3.4	14
85	Licofelone, a Balanced Inhibitor of Cyclooxygenase and 5-Lipoxygenase, Reduces Inflammation in a Rabbit Model of Atherosclerosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 108-116.	2.5	62
86	Proteomics in atherothrombosis: a future perspective. <i>Expert Review of Proteomics</i> , 2007, 4, 249-260.	3.0	13
87	Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques. <i>European Journal of Pharmacology</i> , 2007, 562, 119-129.	3.5	48
88	Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors. <i>Vascular Health and Risk Management</i> , 2007, 3, 521-6.	2.3	15
89	Overexpression of COX-2, Prostaglandin E Synthase-1 and Prostaglandin E Receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: Regulation by nuclear factor-Î². <i>Atherosclerosis</i> , 2006, 187, 139-149.	0.8	84
90	Atorvastatin Reduces the Expression of Prostaglandin E2 Receptors in Human Carotid Atherosclerotic Plaques and Monocytic Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, 60-69.	1.9	70

#	ARTICLE	IF	CITATIONS
91	Vascular Protection of Dual Therapy (Atorvastatin-Amlodipine) in Hypertensive Patients. Journal of the American Society of Nephrology: JASN, 2006, 17, S189-S193.	6.1	11
92	Intensive Treatment With Atorvastatin Reduces Inflammation in Mononuclear Cells and Human Atherosclerotic Lesions in One Month. Stroke, 2005, 36, 1796-1800.	2.0	113
93	HMG-CoA Reductase Inhibitors Reduce Î² Kinase Activity Induced by Oxidative Stress in Monocytes and Vascular Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 2005, 45, 468-475.	1.9	30
94	Quest for Novel Cardiovascular Biomarkers by Proteomic Analysis. Journal of Proteome Research, 2005, 4, 1181-1191.	3.7	80
95	Inflammatory biomarkers and statins. Drugs of Today, 2005, 41, 171.	2.4	3
96	NF-Î² Activation and Fas Ligand Overexpression in Blood and Plaques of Patients With Carotid Atherosclerosis. Stroke, 2004, 35, 458-463.	2.0	91
97	Intensive treatment with statins and the progression of cardiovascular diseases: the beginning of a new era?. Nephrology Dialysis Transplantation, 2004, 19, 2696-2699.	0.7	4
98	Identification by a Differential Proteomic Approach of Heat Shock Protein 27 as a Potential Marker of Atherosclerosis. Circulation, 2004, 110, 2216-2219.	1.6	214
99	Statins in Hypertensive Patients. Drugs, 2004, 64, 61-67.	10.9	5
100	Anti-inflammatory and immunomodulatory effects of statins. Kidney International, 2003, 63, 12-23.	5.2	279
101	Proteomic analysis of human vessels: Application to atherosclerotic plaques. Proteomics, 2003, 3, 973-978.	2.2	107
102	Simvastatin reduces NF-Î² activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovascular Research, 2003, 57, 168-177.	3.8	70
103	Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis, 2002, 160, 49-58.	0.8	116
104	3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase the binding activity and nuclear level of Oct-1 in mononuclear cells. European Journal of Pharmacology, 2002, 448, 113-121.	3.5	12
105	Regulation of matrix proteins and impact on vascular structure. Current Hypertension Reports, 2000, 2, 106-113.	3.5	41
106	Brugada-Like Electrocardiographic Pattern in a Patient With a Mediastinal Tumor. PACE - Pacing and Clinical Electrophysiology, 1999, 22, 1264-1266.	1.2	64
107	Atorvastatin reduces NF-Î² activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis, 1999, 147, 253-261.	0.8	324
108	HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. Journal of the American College of Cardiology, 1998, 32, 2057-2064.	2.8	402

#	ARTICLE	IF	CITATIONS
109	ACE Inhibitor Quinapril Reduces the Arterial Expression of NF- $\kappa$ B-Dependent Proinflammatory Factors but not of Collagen I in a Rabbit Model of Atherosclerosis. American Journal of Pathology, 1998, 153, 1825-1837.	3.8	126
110	Free-floating left atrial thrombus and its mechanical interaction with mitral regurgitant jet assessed by color Doppler echocardiography. American Heart Journal, 1992, 123, 1067-1069.	2.7	1
111	Prolapsing right atrial myxoma evaluated by transesophageal echocardiography. American Heart Journal, 1991, 122, 875-877.	2.7	7